# Mingxin China Growth Fund

> Mingxin China Growth Fund is a VC fund backing Health Care and Biotechnology. See 4 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 4
- Last investment: Jun 2025
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.mcgf.com.cn

Mingxin China Growth Fund is a venture capital firm specializing in growth and expansion stage investments. The firm typically invests in telecommunication, media, technologies; consumer goods and services; healthcare, pharmaceuticals and biotech; clean tech; advanced manufacturing; agriculture; education; and business and financial servicessectors. It seeks to invest in companies based in China. Mingxin China Growth Fund is based in Beijing, China with additional offices in Shanghai, China; Shandong, China; Central, Hong Kong; and Palo Alto, California.

## Contacts

5 contacts available for Mingxin China Growth Fund. Shizune tracks 1 team members at Mingxin China Growth Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mingly-china-growth-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Internet | 1 | 25% |
| Software | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 25% |
| Funding Round | 1 | 25% |
| Private Equity | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 50% |
| United States | 2 | 50% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jim Boettcher | Co-Founder & Chairman Investment Committee | 1 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vor Biopharma | Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) Tcells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies. | $175M | Post-IPO Equity | Jun 24, 2025 |  |
| Remegen | RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates(ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California. |  | Private Equity | Dec 07, 2019 |  |
| PegBio | Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an agonist of glucagon-like peptide 1 (GLP-1), allows diabetes patients to take medicine once a week, instead of requiring daily injections. | $992K | Series C | Oct 15, 2015 |  |
| ASSIA | ASSIA, Inc provides broadband and Wi-Fi performance monitoring, management and optimization software to internet service providers (ISP), communications regulators, and wholesalers so they can improve customer quality of experience and satisfaction, reduce costs through operational efficiencies and increase revenues with new multi-media services. | $10M |  | Nov 02, 2009 |  |

4 of 4 investments shown.

## Co-investors
- [Caligan Partners](https://shizune.co/investors/profile/caligan-partners) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together
- [GF Venture Capital](https://shizune.co/investors/profile/gf-venture-capital) — VC Fund, 1 deal together
- [Huatai Health Fund](https://shizune.co/investors/profile/huatai-ruihe-healthcare-industrial-fund) — VC Fund, 1 deal together
- [Lapam Capital](https://shizune.co/investors/profile/lapam-capital) — VC Fund, 1 deal together
- [Lucion](https://shizune.co/investors/profile/lucion) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Mingxin China Growth Fund invest in?

Mingxin China Growth Fund invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series C and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mingxin China Growth Fund?

Public channels for Mingxin China Growth Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mingxin China Growth Fund?

The team at Mingxin China Growth Fund includes Jim Boettcher (Co-Founder & Chairman Investment Committee). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co